Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial

About this Attention Score

• In the top 5% of all research outputs scored by Altmetric
• Among the highest-scoring outputs from this source (#18 of 1,020)
• High Attention Score compared to outputs of the same age (99th percentile)